Seminars in Oncology
Volume 34, Issue 6 , Pages 532-545 , December 2007

Management of Metastatic Melanoma

  • Hussein A. Tawbi
    • ,
  • John M. Kirkwood

      Affiliations

    • Corresponding Author InformationAddress correspondence to John M. Kirkwood, MD, Department of Medicine, University of Pittsburgh School of Medicine, Hillman Cancer Reseach Pavilion Suite L1.32c, 5117 Centre Ave, Pittsburgh PA 15213-2584.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Luce JK, Thurman WG, Isaacs BL, et al. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). Cancer Chemother Rep. 1970;54:119–124
  3. Costanza ME, Nathanson L, Lenhard R, et al. Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea. Cancer. 1972;30:1457–1461
  4. Nathanson L, Wolter J, Horton J, et al. Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma. Clin Pharmacol Ther. 1971;12:955–962
  5. Carter RD, Krementz ET, Hill GJ, et al. DTIC (nsc-45388) and combination therapy for melanoma (I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065)). Cancer Treat Rep. 1976;60:601–609
  6. Del Prete SA, Maurer LH, O’Donnell J, et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984;68:1403–1405
  7. Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999;17:1884–1890
  8. Jungnelius U, Ringborg U, Aamdal S, et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma (A randomised phase III trial). Eur J Cancer. 1998;34:1368–1374
  9. Jelic S, Babovic N, Kovcin V, et al. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: A single-centre randomized four-arm study. Melanoma Res. 2002;12:91–98
  10. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002;20:1600–1607
  11. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol. 2002;20:2045–2052
  12. Agarwala SS, Ferri W, Gooding W, et al. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999;85:1979–1984
  13. Ravaud A, Delaunay M, Chevreau C, et al. Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: A randomized phase II trial. Br J Cancer. 2001;85:1467–1471
  14. Chiarion Sileni V, Nortilli R, Aversa SM, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res. 2001;11:189–196
  15. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–2751
  16. O’Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A:940–942
  17. Newlands ES, O’Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996;32A:2236–2241
  18. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65(2):287–291
  19. Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35–61
  20. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13:910–913
  21. Middleton MR, Lunn JM, Morris C, et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer. 1998;78:1199–1202
  22. Middleton MR, Kelly J, Goodger S, et al. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. Cancer Chemother Pharmacol. 2000;45:15–20
  23. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest. 2003;21:821–829
  24. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol. 2004;22:2101–2107
  25. Tas F, Argon A, Camlica H, et al. Temozolomide in combination with cisplatin in patients with metastatic melanoma: A phase II trial. Melanoma Res. 2005;15:543–548
  26. Daponte A, Ascierto PA, Gravina A, et al. Temozolomide and cisplatin in avdanced malignant melanoma. Anticancer Res. 2005;25:1441–1447
  27. Bafaloukos D, Tsoutsos D, Kalofonos H, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: A randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16:950–957
  28. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873–1878
  29. Calabresi F, Aapro M, Becquart D, et al. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol. 1991;2:377–378
  30. Schallreuter KU, Wenzel E, Brassow FW, et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol. 1991;29:85–87
  31. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol. 2004;22:1118–1125
  32. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst. 1991;83:288–291
  33. Horwitz SB. Mechanism of action of Ttaxol. Trends Pharmacol Sci. 1992;13:134–136
  34. Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol. 1987;5:1232–1239
  35. Legha SS, Ring S, Papadopoulos N, et al. A phase II trial of Taxol in metastatic melanoma. Cancer. 1990;65:2478–2481
  36. Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs. 1991;9:59–64
  37. Zonder JA, Heilburn L, Flaherty LE, et al. Phase II trial of weekly paclitaxel as 2nd line treatment of metastatic malignant melanoma. LP Proc Am Soc Clin Oncol. 2000;19:571;(abstr 2249)
  38. Walker L, Schalch H, King DM, et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res. 2005;15:453–459
  39. Bedikian AY, Plager C, Papadopoulos N, et al. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14:63–66
  40. Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: A new active combination for disseminated malignant melanoma. Anticancer Drugs. 1996;7:161–165
  41. Nathan FE, Berd D, Sato T, Mastrangelo MJ. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer. 2000;88(1):79–87
  42. Feun LG, Savaraj N, Hurley J, et al: Phase II trial of paclitaxel and dacarbazine with filgrastim administration in advanced malignant melanoma. Cancer Invest 20:357-361, 002
  43. Hodi FS, Soiffer RJ, Clark J, et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25:283–286
  44. Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003;13:531–536
  45. Einzig AI, Schuchter LM, Recio A, et al. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol. 1996;13:111–117
  46. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995;13:2895–2899
  47. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: A phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30A:1061–1064
  48. Bafaloukos D, Gogas H, Georgoulias V, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol. 2002;20:420–425
  49. Walpole ET, Godwin S, Humphreys D. Phase I-II study of dacarbazine with docetaxel for metastatic melanoma. TD Proc Am Soc Clin Oncol. 2003;22:(abstr 2893)
  50. Bafaloukos D, Aravantinos G, Fountzilas G, et al. Docetaxel in combination with dacarbazine in patients with advanced melanoma. Oncology. 2002;63:333–337
  51. Fruehauf JP KK, Jakowatz JG: Phase II study of docetaxel and vinorelbine plus GM-CSF in malignant melanoma. Presented at the 2006 American Society of Clinical Oncology Annual Meeting, Atlanta, GA
  52. Tas F, Camlica H, Kurul S, et al. Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma. Clin Oncol. 2003;15:132–135
  53. Ledda F, Bravo AI, Adris S, et al. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol. 1997;108:210–214
  54. Massi D, Franchi A, Borgognoni L, et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999;30:339–344
  55. Hersh E, Gonzalez R, Ribas A, et al. Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy naive patients with metastatic melanoma. Melanoma Res. 2006;16(suppl 1):S78
  56. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep. 1982;66:31–35
  57. Schilcher RB, Wessels M, Niederle N, et al. Phase II evaluation of fractionated low and single high dose cisplatin in various tumors. J Cancer Res Clin Oncol. 1984;107:57–60
  58. Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5:574–578
  59. Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep. 1987;71:171–172
  60. Guven K, Kittler H, Wolff K, et al. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res. 2001;11:411–415
  61. Retsas S, Newton KA, Westbury G. Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol. 1979;2:257–260
  62. Arseneau JC, Mellette SJ, Kuperminc M, et al. Phase II study of vindesine in metastatic malignant melanoma. Cancer Treat Rep. 1981;65:355–356
  63. Camacho FJ, Young CW, Wittes RE. Phase II trial of vindesine in patients with malignant melanoma. Cancer Treat Rep. 1980;64:179–181
  64. Smith IE, Hedley DW, Powles TJ, et al. Vindesine: A phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors. Cancer Treat Rep. 1978;62:1427–1433
  65. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med. 1981;95:414–420
  66. Carmichael J, Atkinson RJ, Calman KC, et al. A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol. 1982;18:1293–1295
  67. Emmert S, Zutt M, Haenssle H, et al. Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents. Melanoma Res. 2003;13:299–302
  68. Whitehead RP, Moon J, McCachren SS, et al. A phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: A Southwest Oncology Group study. Cancer. 2004;100:1699–1704
  69. Thompson JA, Gold PJ, Fefer A. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol. 1997;24(suppl 4):S44–S48
  70. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two phase II Cytokine Working Group trials. J Clin Oncol. 2001;19:3194–3202
  71. Khayat D, Antoine E, Rixe O, et al. Chemoimmunotherapy of metastatic malignant melanoma (The Salpetriere Hospital (SOMPS) experience). Eur J Cancer. 1993;29A(suppl 5):S2–S5
  72. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996;7:827–835
  73. Richards JM, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992;10:1338–1343
  74. Atkins MB, O’Boyle KR, Sosman JA, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994;12:1553–1560
  75. Thompson JA, Gold PJ, Markowitz DR, et al. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am. 1997;3(suppl 1):S29–S34
  76. Neri B, Vannozzi L, Fulignati C, et al. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: Report of a phase II study. Cancer Invest. 2006;24:474–478
  77. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752–1759
  78. McDermott DF, Mier JW, Lawrence DP, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res. 2000;6:2201–2208
  79. Atkins MB, Lee S, Flaherty LE, et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2, and interferon alpha-2B (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol. 2003;22:(abstr 2847)
  80. Keilholz U, Stoter G, Punt CJ, et al. Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am. 1997;3(suppl 1):S22–S28
  81. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005;23:6747–6755
  82. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17:968–975
  83. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol. 2006;17:571–577
  84. Ron IG, Sarid D, Ryvo L, et al. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: A phase II study. Melanoma Res. 2006;16:65–69
  85. Garcia M, del Muro XG, Tres A, et al. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. Melanoma Res. 2006;16:365–370
  86. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001–9007
  87. Hwu WJ, Panageas KS, Menell JH, et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006;106:2445–2451
  88. Agarwala SS TA, Kirkwood JM, Cai C, et al: Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HDB) IL-2 in patients with metastatic melanoma. Presented at the 2006 American Society of Clinical Oncology Annual Meeting, Atlanta, GA
  89. El-Maraghi RVS, Charette M, Markman B, et al: A meta-analysis of biochemotherapy (BCT) for the treatment of metastatic malignant melanoma (MM). ASCO Annual Meeting, July 15, 2004, New Orleans, LA (suppl)
  90. Agarwala S, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol. 2007;25(suppl 18S):8510
  91. Eisen T, Marais R, Affolter A, et al. An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J Clin Oncol. 2007;25(suppl 18S):8529
  92. McDermott DF, Sosman J, Hodi FS, et al. Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J Clin Oncol. 2007;25(suppl 18S):8511
  93. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738–4745
  94. Cranmer L, Bedikian AY, Ribas A, et al. Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma. J Clin Oncol. 2006;25(suppl 18S):8011
  95. Hersey P, Sosman J, O’Day S, et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol. 2005;23(suppl 16S):7507
  96. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47:5846–5852
  97. Riazuddin S, Athar A, Saffhill R. Chemical adaptation of M. luteus induces repair functions for O-alkylated DNA pyrimidines. Nucleic Acids Res. 1985;13:7153–7166
  98. Humbert O, Fiumicino S, Aquilina G, et al. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis. 1999;20:205–214
  99. Liu L, Gerson SL. Targeted modulation of MGMT: Clinical implications. Clin Cancer Res. 2006;12:328–331
  100. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995;51:167–223
  101. Ayi TC, Loh KC, Ali RB, et al. Intracellular localization of human DNA repair enzyme methylguanine-DNA methyltransferase by antibodies and its importance. Cancer Res. 1992;52:6423–6430
  102. Smith DC, Gerson SL, Liu L, et al. Carmustine and streptozocin in refractory melanoma: An attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 1996;2:1129–1134
  103. Lee SM, Thatcher N, Margison GP. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res. 1991;51:619–623
  104. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363–4367
  105. Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000;6:3025–3031
  106. Ranson M, Middleton MR, Bridgewater J, et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2006;12:1577–1584
  107. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res. 2000;461:83–108
  108. Prasad R, Lavrik OI, Kim SJ, et al. DNA polymerase beta-mediated long patch base excision repair (Poly(ADP-ribose)polymerase-1 stimulates strand displacement DNA synthesis). J Biol Chem. 2001;276:32411–32414
  109. Wang ZQ, Auer B, Stingl L, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995;9:509–520
  110. Plummer R, Lorigan P, Evens J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Clin Oncol. 2006;24:8013;(suppl 18S, abstr)
  111. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–1011
  112. Tentori L, Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med. 2002;9:1285–1301
  113. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol. 2005;32:521–530
  114. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–6044
  115. Korn EL, Liu P-Y, Lee S, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma: Determining progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2007;(in press)

PII: S0093-7754(07)00184-4

doi: 10.1053/j.seminoncol.2007.09.008

Seminars in Oncology
Volume 34, Issue 6 , Pages 532-545 , December 2007

Article Tools

* Image Usage & Resolution